Literature DB >> 21632889

Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.

Maryam Imam1, Yengkhom Sangeeta Devi, Akhilesh K Verma, Virander Singh Chauhan.   

Abstract

Recombinant Plasmodium falciparum merozoite surface protein 3 (PfMSP3F) and a 24-kDa fragment from its N terminus (MSP3N) that includes the essential conserved domain, which elicits the maximum antibody (Ab)-dependent cellular inhibition (ADCI), were expressed as soluble proteins in Escherichia coli. Both proteins were found to be stable in both soluble and lyophilized forms. Immunization with MSP3F and MSP3N formulated separately with two human-compatible adjuvants, aluminum hydroxide (Alhydrogel) and Montanide ISA 720, produced significant antibody responses in mice and rabbits. Polyclonal Abs against both antigens recognized native MSP3 in the parasite lysate. These two Abs also recognized two synthetic peptides, previously characterized to possess B cell epitopes from the N-terminal region. Antibody depletion assay showed that most of the IgG response is directed toward the N-terminal region of the full protein. Anti-MSP3F and anti-MSP3N rabbit antibodies did not inhibit merozoite invasion or intraerythrocytic development but significantly reduced parasitemia in the presence of human monocytes. The ADCI demonstrated by anti-MSP3N antibodies was comparable to that exhibited by anti-MSP3F antibodies (both generated in rabbit). These results suggest that the N-terminal fragment of MSP3 can be considered a vaccine candidate that can form part of a multigenic vaccine against malaria.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632889      PMCID: PMC3147339          DOI: 10.1128/CVI.00064-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  25 in total

1.  Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.

Authors:  Hajime Hisaeda; Allan Saul; Joshua J Reece; Michael C Kennedy; Carole A Long; Louis H Miller; Anthony W Stowers
Journal:  J Infect Dis       Date:  2002-02-14       Impact factor: 5.226

2.  Toward the rational design of a malaria vaccine construct using the MSP3 family as an example: contribution of antigenicity studies in humans.

Authors:  Corine G Demanga; Lena-Juliette Daher; Eric Prieur; Catherine Blanc; Jean-Louis Pérignon; Hasnaa Bouharoun-Tayoun; Pierre Druilhe
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

3.  Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule.

Authors:  Brandt R Burgess; Peter Schuck; David N Garboczi
Journal:  J Biol Chem       Date:  2005-08-31       Impact factor: 5.157

4.  Malaria vaccine development based on merozoite surface proteins of Plasmodium falciparum.

Authors:  Virander S Chauhan; Syed Shams Yazdani; Deepak Gaur
Journal:  Hum Vaccin       Date:  2010-09-13

5.  Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure.

Authors:  Chiawei W Tsai; Peter F Duggan; Albert J Jin; Nicholas J Macdonald; Svetlana Kotova; Jacob Lebowitz; Darrell E Hurt; Richard L Shimp; Lynn Lambert; Louis H Miller; Carole A Long; Allan Saul; David L Narum
Journal:  Mol Biochem Parasitol       Date:  2008-11-27       Impact factor: 1.759

6.  Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.

Authors:  Soe Soe; Michael Theisen; Christian Roussilhon; Khin-Saw Aye; Pierre Druilhe
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design.

Authors:  Subhash Singh; Soe Soe; Juan-Pedro Mejia; Christian Roussilhon; Michael Theisen; Giampietro Corradin; Pierre Druilhe
Journal:  J Infect Dis       Date:  2004-07-27       Impact factor: 5.226

8.  Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection.

Authors:  Spencer D Polley; Kevin K A Tetteh; Jennie M Lloyd; Onome J Akpogheneta; Brian M Greenwood; Kalifa A Bojang; David J Conway
Journal:  J Infect Dis       Date:  2006-12-13       Impact factor: 5.226

9.  Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages.

Authors:  H Bouharoun-Tayoun; C Oeuvray; F Lunel; P Druilhe
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

10.  Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3.

Authors:  F H A Osier; S D Polley; T Mwangi; B Lowe; D J Conway; K Marsh
Journal:  Parasite Immunol       Date:  2007-08       Impact factor: 2.280

View more
  7 in total

1.  Plasmodium falciparum merozoite surface protein 3: oligomerization, self-assembly, and heme complex formation.

Authors:  Maryam Imam; Shailja Singh; Naveen Kumar Kaushik; Virander Singh Chauhan
Journal:  J Biol Chem       Date:  2013-12-19       Impact factor: 5.157

Review 2.  Malaria evolution in South Asia: knowledge for control and elimination.

Authors:  Krishnamoorthy Narayanasamy; Laura Chery; Analabha Basu; Manoj T Duraisingh; Ananias Escalante; Joseph Fowble; Jennifer L Guler; Thurston Herricks; Ashwani Kumar; Partha Majumder; Jennifer Maki; Anjali Mascarenhas; Janneth Rodrigues; Bikram Roy; Somdutta Sen; Jayanthi Shastri; Joseph Smith; Neena Valecha; John White; Pradipsinh K Rathod
Journal:  Acta Trop       Date:  2012-01-14       Impact factor: 3.112

3.  Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.

Authors:  Puneet K Gupta; Paushali Mukherjee; Shikha Dhawan; Alok K Pandey; Suman Mazumdar; Deepak Gaur; S K Jain; Virander S Chauhan
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

4.  The origin and diversification of the merozoite surface protein 3 (msp3) multi-gene family in Plasmodium vivax and related parasites.

Authors:  Benjamin L Rice; Mónica M Acosta; M Andreína Pacheco; Jane M Carlton; John W Barnwell; Ananias A Escalante
Journal:  Mol Phylogenet Evol       Date:  2014-05-23       Impact factor: 4.286

5.  Plasmodium falciparum MSP3 Exists in a Complex on the Merozoite Surface and Generates Antibody Response during Natural Infection.

Authors:  Arunaditya Deshmukh; Bishwanath Kumar Chourasia; Sonali Mehrotra; Ikhlaq Hussain Kana; Gourab Paul; Ashutosh Panda; Inderjeet Kaur; Susheel Kumar Singh; Sumit Rathore; Aparup Das; Priya Gupta; Md Kalamuddin; S K Gakhar; Asif Mohmmed; Michael Theisen; Pawan Malhotra
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

6.  Genetic diversity of the merozoite surface protein-3 gene in Plasmodium falciparum populations in Thailand.

Authors:  Sittiporn Pattaradilokrat; Vorthon Sawaswong; Phumin Simpalipan; Morakot Kaewthamasorn; Napaporn Siripoon; Pongchai Harnyuttanakorn
Journal:  Malar J       Date:  2016-10-21       Impact factor: 2.979

7.  Antibody Combinations Targeting the Essential Antigens CyRPA, RH5, and MSP-119 Potently Neutralize Plasmodium falciparum Clinical Isolates From India and Africa.

Authors:  Hina Singh; Syed Yusuf Mian; Alok K Pandey; Sri Krishna; Gaurav Anand; K Sony Reddy; Neha Chaturvedi; Vanndita Bahl; Nidhi Hans; Man Mohan Shukla; Quique Bassat; Alfredo Mayor; Kazutoyo Miura; Praveen K Bharti; Carole Long; Neeru Singh; Virander Singh Chauhan; Deepak Gaur
Journal:  J Infect Dis       Date:  2021-06-04       Impact factor: 5.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.